psychedelic medicine – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Thu, 01 Dec 2022 18:33:36 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine https://mjshareholders.com/silo-pharma-issues-letter-to-shareholders-detailing-progress-on-pipeline-assets-combining-traditional-therapeutics-with-psychedelic-medicine/ Thu, 01 Dec 2022 18:33:36 +0000 https://www.cannabisfn.com/?p=2970447

Ryan Allway

December 1st, 2022

Psychedelics, Top News


ENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. ( Nasdaq: SILO ) (“the Company”) , a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today issued a letter to shareholders highlighting the Company’s progress and potential for its portfolio of novel, IP-protected technologies and assets developed in collaboration with world-class medical research partners. The letter, in its entirety, is reprinted below.

Dear fellow Silo Pharma shareholders,

The healthcare market continues to build momentum as science and technology lead to new developments for therapeutics. Nowhere is this more evident than in the growing body of scientific research supporting the therapeutic potential of psychedelics. More than ever, alternative new therapies for numerous diseases and mental health disorders are needed to address the health challenges of today.

Our Company, Silo Pharma, Inc. (Nasdaq: SILO) is working diligently to make further advances in the medical and psychedelic space. To date, the research conducted has shown encouraging promise in the delivery, efficacy, and safety of our pipeline therapeutics and technologies.

This has been an exciting year where we have achieved numerous milestones and anticipate upcoming updates as our pipeline progresses. The purpose of this letter is to provide shareholders with an update on our current business. With over $12 million in cash, we are prepared to advance our pipeline, and believe, with our strong balance sheet, no debt, and recent listing on Nasdaq, that we are in a position to further advance the Company and create shareholder value.

Valuable Intellectual Property and Collaboration

We are focused on advancing traditional therapeutics with psychedelic research to treat underserved large markets. We believe that our novel IP-protected technologies and assets, developed in collaboration with world-class medical research partners, offer disruptive market potential.

The unique assets in our portfolio are well protected with issued and numerous provisional patents pending. We obtained these assets through exclusive drug development collaborations, including a joint venture with Zylö Therapeutics, Inc.; a license and option agreement and an investigator-sponsored study agreement with the University of Maryland, Baltimore; a sponsored study agreement and a licensing option agreement with Columbia University; and a sponsored research agreement with the University of California, San Francisco.

Several of our therapeutics may qualify us to pursue the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval. This new drug application (NDA) process avoids unnecessary duplication of studies already performed on a previously approved drug, potentially saving clinical time and providing significant cost savings.

Potentially Transformative Assets with Disruptive Market Opportunity

SP-26 — F ibromyalgia

With our joint venture with Zylö Therapeutics, we are developing ketamine for sustained release which utilizes our partner’s Z-pod® technology, a topical drug delivery system developed at the Albert Einstein College of Medicine. Preclinical studies have already shown that the Z-pod can hold and distribute our proprietary ketamine formulation in a time-released manner. Topical administration of ketamine using this technology (designated as SP-26 by Silo Pharma) yielded neuropathic nerve pain reduction in a small animal study — positive results that could be promising for patients suffering from fibromyalgia, our initial indication. A safety evaluation study is currently underway to determine the maximum tolerated dosing data to be utilized in future trials.

We recently began working with our regulatory partner to prepare a pre-Investigational New Drug (IND) package for submission to support getting SP-26 into the clinic.

SPU-16 — M ultiple S clerosis (MS)

Last year, we entered into a license agreement with the University of Maryland, Baltimore (UMB) to examine a patented novel homing peptide for CNS also known as central nervous system (CNS) homing peptides (SPU-16), designed to access through the blood-brain barrier and then home to specific damaged tissue. Animal study results of the homing peptides have shown potential improved delivery of therapeutics and decreased toxicity. Our initial indication is MS.

SPU-21 — R heumatoid A rthritis (RA)

Under a separate commercial evaluation license agreement (CELA) with UMB, we are exploring the use of joint homing peptides (SPU-21) to deliver targeted therapeutics for the treatment of rheumatoid arthritis (RA), an autoimmune disorder. SPU-21 has been shown to inhibit arthritic progression in a preclinical animal model.

SPC-14 — Alzheimer’s Disease (AD)

Last year, we entered a CELA with Columbia University for two therapeutics. The agreement includes an option to license an Alzheimer’s disease therapeutic currently under development.

We recently announced proof-of-concept data supporting the therapeutic potential of this drug candidate (SPC-14) as a treatment for Alzheimer’s disease, as demonstrated in a mouse model. With safety data already available from the FDA-approved therapeutics in the compound, we believe that SPC-14 should be eligible for development under the FDA’s 505(b)(2) regulatory pathway.

SPC-15 — Stress Induced anxiety disorder and PTSD

Our second study with Columbia University examines a targeted prophylactic using ketamine compositions as a method of treatment and prevention for stress-induced affective disorders including post-traumatic stress disorder (PTSD). This treatment (SPC-15) predicts levels of severity or progression of such disorders, and their metabolomic biomarkers response to pharmacological treatments. Based on the research to date, SPC-15 could have an impact on treating stress and anxiety disorders.

Clinical S tudy — E ffects of P silocybin on I nflammatory A ctivity

We have sponsored a clinical study on the effects psilocybin may have on inflammation in the body under a sponsored research agreement with the University of California San Francisco. The study aims to support the implementation of psilocybin as a potential therapeutic for inflammation. The data from this study could provide support for the anti-inflammatory effect of psilocybin.

Therapies Target Underserved Medical Markets

The burgeoning psychedelic drugs market was valued at $2.8 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 17% to $9.8 billion in 2029. Against this landscape, the disease targets for our drug candidates represent large, underserved medical markets. Following are some facts and figures.

  • Our initial indication for SP-26 is fibromyalgia , a disorder affecting about 4 million American adults, or about 2% of the adult population. It is a chronic condition causing pain to the connective tissues throughout the body including muscles, ligaments, and tendons. Musculoskeletal pain is often accompanied by sleep difficulties, fatigue, mood disorders, and problems with memory and concentration. According to Fortune Business Insights, the fibromyalgia treatment market is projected to grow from $764.1 million in 2020 to $1.4 billion in 2027, at a CAGR of 9.2% in the 2020-2027 period. 2
  • SPU-16 targets multiple sclerosis , a debilitating neurological condition that causes the disruption of signal transmitting by the nervous system. Damage to the nerve fibers may cause fatigue, numbness and tingling, weakness, poor coordination, pain, depression, and problems with memory and concentration. As the most widespread disabling neurological condition of young adults, MS affects nearly a million Americans and approximately 2.8 million people worldwide. A report by Fortune Business Insights states that the global multiple sclerosis drugs market is projected to grow from $25.4 billion in 2022 to $33.2 billion by 2029, at a CAGR of 3.9%. 3
  • SPU-21 targets rheumatoid arthritis , the most common autoimmune disease in the U.S. affecting around 1.5 million adults. RA is a systemic disease, but most often the immune system will attack the inner lining of the joints bringing pain, swelling, and stiffness that can be debilitating. A 2022 report published by Precedence Research states that the global rheumatoid arthritis drugs market size is expected to reach $70 billion by 2030 with a CAGR of 1.7% in that time period. 4
  • Targeted by SPC-14, Alzheimer’s disease is an irreversible, progressive brain disorder that is the leading cause of dementia in older adults. AD and related diseases affect more than 6.5 million Americans over the age of 65, or about one in every nine Americans aged 65+. The loss of memory from AD is due to plaque, tangles, or loss of connections within the neural brain cells, which can also affect language, reasoning, visual/spatial skills, and mood. According to Growth+ Reports, the U.S. market for AD drugs is growing at a CAGR of over 7% and is expected to reach $9.7 billion by 2031. 5

    Targeted by SPC-15, anxiety, PTSD, and other stress-related disorders are becoming more frequent in Americans aged 18+. According to the World Health Organization in 2019, 300+ million people were living with an anxiety disorder, and according to the National Center for PTSD, around 12 million adults in the U.S. alone are reported to have PTSD. 6 , 7 According to Fortune Business Insights, the global treatment market size for anxiety disorders and depression is projected to reach $13.0 billion in 2027.

Our financial position and balance sheet are strong with zero debt. We own intellectual property and technology rights. We believe our diversified therapeutic candidates have disruptive market potential and offer potentially groundbreaking treatment options for some of the most debilitating diseases and conditions.

We are deeply grateful to our shareholders and appreciate your continued support. We look forward to keeping you informed about the progress of our studies as we advance our programs toward the clinic. This is an exciting and transformative time for our Company.

With best regards,

Eric Weisblum
Chief Executive Officer

About Ketamine
Ketamine is an FDA-approved fast-acting general anesthetic administered through intravenous injection or nasal spray (milder form). Scientific research has shown that ketamine’s interactions with certain brain chemicals may be connected to its pain management, anti-inflammatory, and antidepressant effects. Since 2000, increasing research on ketamine has demonstrated significant results as a treatment for pain conditions including chronic neuro-inflammatory disorders and for mood disorders including depression, PTSD, and anxiety.

About Psilocybin
Considered a serotonergic hallucinogen, this substance is an active ingredient in some species of mushrooms. While classified as a Schedule I controlled substance under the Controlled Substances Act (CSA), there is an accumulating body of evidence that psilocybin may have beneficial effects on depression and other mental health conditions. The U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Agency (DEA) have permitted the use of psilocybin in clinical studies for a range of psychiatric conditions.

About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com.

Forward-Looking Statements
This communication contains forward-looking statements concerning the Company’s collaborations, business and development plans, and statements regarding the Company’s product candidates, their development, regulatory plans with respect thereto and therapeutic potential thereof, planned interactions with regulatory authorities, and planned clinical development. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the Company’s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, the Company’s ability to identify additional product candidates for development, the Company’s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, competition in the industry in which the Company operates and market conditions. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in our Annual Report on Form 10-K for the year ended December 31, 2021, and other periodic reports filed with the Securities and Exchange Commission available at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof, and we specifically disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact
800-705-0120
[email protected]

Data Bridge Market Research. September 2022
Fortune Business Insights; Fibromyalgia Treatment Market Size, Share and Trends. September 2022.
Fortune Business Insights; Multiple Sclerosis Drugs Market Size, Share… May 2022.
Precedence Research; Rheumatoid Arthritis Drugs Market, Report 2022-2030. June 2022.
Growth+ Reports; Alzheimer’s Drugs Market by Drug Type … Global Outlook & Forecast 2021-2031. March 2020.
World Health Organization; Mental disorders. June 2022.
U.S. Department of Veterans Affairs, PTSD: National Center for PTSD; How Common Is PTSD in Adults?

News Provided by GlobeNewswire via QuoteMedia

Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.

-Coach

 

Joe Reda

Founder/Partner

The Special Equities Group “SEG”

 

One Wolfs Lane

Suite 316

Pelham, NY 10803

 

O: 212-258-2341

C: 516-521-1354

 

[email protected]

 

www.theseg.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Clearmind Medicine Engages Bar-Ilan University to Evaluate Anti-Addictive Properties of Clearmind’s Proprietary MEAI Compound https://mjshareholders.com/clearmind-medicine-engages-bar-ilan-university-to-evaluate-anti-addictive-properties-of-clearminds-proprietary-meai-compound/ Thu, 18 Nov 2021 17:14:32 +0000 https://www.cannabisfn.com/?p=2935993

Ryan Allway

November 18th, 2021

Psychedelics


Professor Gal Yadid, renowned neuropsychopharmacologist, to spearhead the project

Toronto, Ontario–(Newsfile Corp. – November 18, 2021) – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC Pink: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces it has signed an R&D agreement with Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel) to advance the evaluation of its MEAI compound as a potential treatment for addiction and other binge behaviors.

According to the United Nations Office on Drugs and Crime’s “2021 World Drug Report”, over 36 million people suffered from drug use disorders. While some substances are more concerning than others, i.e., drugs and alcohol, addiction and abusive behavior is not limited to these substances. Compulsive consumption of food, shopping, gambling, sex, television, and technology, many of which increased in prevalence during the recent pandemic, can all be destructive when their use cannot be managed.

A prominent figure in the research and development of treatments for psychiatric disease, specifically drug addiction, depression, and PTSD, Professor Gal Yadid, which is also a member of the Company’s SAB, and his team will conduct a series of studies to verify the mechanism of action and specific neural targets of MEAI and evaluate its efficacy as potential therapeutic agent in the treatment of addiction and related behaviors.

Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented on the announcement, “Professor Yadid is a pioneer in the field and I am thrilled that he has agreed to help move our research forward. His contributions to the understanding and treatment of addiction inform the work we are doing at Clearmind and I look forward to working with him and his team at Bar Ilan University.”

Professor Yadid added, “Many conventional treatments for addiction are not effective – some I might argue, are in fact detrimental to recovery. My research takes a neuropsychopharmacological approach to treating mental health disorders; once we have identified the altered brain pathways related to a specific condition, I hope we can use compounds like MEAI to manipulate these pathways to help manage or even eliminate the maladapted behaviors.”

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of four patent families. The first, “Binge Behavior Regulators”, has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute”, has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND“, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol “CMNDF

For further information, please contact:
Investor Relations,
Email: [email protected]
Telephone: (778) 400-5347
General Inquiries,
[email protected]
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE“) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development https://mjshareholders.com/caamtech-raises-22-million-for-psychedelic-drug-discovery-and-development/ Fri, 10 Sep 2021 21:23:33 +0000 https://www.cannabisfn.com/?p=2933305

Ryan Allway

September 10th, 2021

Psychedelics


The investment provides CaaMTech with capital to advance compounds from its library into clinical trials

ISSAQUAH, Wash., Sept. 08, 2021 (GLOBE NEWSWIRE) — CaaMTech, Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing round, led by Noetic Fund. The oversubscribed round of funding will be deployed to support CaaMTech’s industry-leading cross-disciplinary science program, expand the company’s leadership team, and advance its foremost drug development candidates into human trials.

“This Series A investment further substantiates our hypothesis that the future of the psychedelics industry depends on the strength of its foundation,” said CaaMTech founder and CEO, Dr. Andrew Chadeayne. “Now that we have built that foundation, we are grateful to partner with Noetic for the next steps. Their industry leadership and experienced team make Noetic the optimal partner to help shepherd these drugs to the patients who need them most.”

CaaMTech was founded in 2017 to fill the unmet need for pure, well-characterized psychedelic drugs. Since then, the company has produced an extensive library of novel, analytically pure compounds that are nearing advancement into human trials.

“CaaMTech’s extensive patent library, scientific and research-laden focus, coupled with their impressive leadership team and an unwavering commitment to pursuing drug development within the psychedelic industry make them one of the most formidable companies in this space,” said Sa’ad Shah, co-founder and managing partner of the Noetic Fund. “We could not be more excited about our support and investment in CaaMTech.”

CaaMTech has led the psychedelics industry in fundamental research, publishing tens of peer-reviewed scientific research publications. Through collaborations with the NIH’s Designer Drug Research Unit at the National Institute on Drug Abuse, the University of Massachusetts Dartmouth, and The Leibniz Institute for Natural Product Research, CaaMTech has built a cross-disciplinary team of world-class scientists, providing diverse subject matter expertise and a shared goal to advance the state of the art of the psychedelic industry. The successful completion of Series A funding will allow CaaMTech to continue its dedication to fundamental scientific research through continued academic collaboration while advancing individual drug candidates toward the clinic.


About CaaMTech
CaaMTech is the foremost drug discovery and lead optimization company focused on engineering psychedelic drugs that meet the standards of modern medicine. CaaMTech is improving the health and happiness of humankind by creating and optimizing psychedelic compounds and formulations through rigorous science and continuous innovation.

About Noetic
Noetic is a group of venture funds launched by Grey House Partners GP Inc. to invest in emerging and early-stage psychedelic and CNS companies, addressing global unmet healthcare needs such as mental health conditions, substance use disorders, and distinct inflammatory-related ailments. Noetic has built a team with the deep domain expertise required to appraise opportunities in this nascent sector: from neuroscience and pharmacology through to regulatory pathways and health economics. The firm is committed to scaling the disruptive potential of psychedelics in a responsible manner, with a core mission of supporting the development of innovative technologies that help define a healthy future for people and the planet.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Clearmind Announces Changes To Senior Management As It Accelerates Development Of Its IP Portfolio https://mjshareholders.com/clearmind-announces-changes-to-senior-management-as-it-accelerates-development-of-its-ip-portfolio/ Wed, 14 Jul 2021 21:43:50 +0000 https://www.cannabisfn.com/?p=2926146

Ryan Allway

July 14th, 2021

Psychedelics


Industry Veteran Dr. Adi Zuloff-Shani Takes The Helm As CEO

Toronto, Ontario–(Newsfile Corp. – July 14, 2021) –  Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce changes to its executive management team in conjunction with an accelerated effort to execute the strategic shift to psychedelic drug development as defined in its May 25th Change of Business listing on the Canadian Stock Exchange.

Dr. Adi Zuloff-Shani, PhD., a biomedical research and development executive with over 20 years of strategic and operational leadership in the healthcare industry, has been appointed as Chief Executive Officer. Dr. Zuloff-Shani has extensive experience successfully navigating the highly regulated process of taking therapeutics from discovery to commercialization.

Oz Locker, a proven entrepreneur with significant managerial and operational experience, has been appointed Chief Operating Officer. Mr. Locker most recently served as the CEO of a fully integrated CBD company in the U.S, and prior, he served in several leadership positions in fast growing technological startups. Oz is a veteran Air-Force pilot and has earned his MBA from Harvard Business School.

Gadi Levin, a Qualified Chartered Accountant with over 25 years’ experience in senior financial positions, will become the Company’s Chief Financial Officer. Mr. Levin has served as CFO of several North American publicly listed companies as well as Vice President of Finance and CFO for two Israeli investment houses focused on private equity, hedge funds and real estate and regularly consults with start-up and earlier stage companies.

Ezekiel Golan, inventor of the technology underlying the Company’s Binge Behavior Regulators, will now serve only as a Special Advisor for Innovation and New Initiatives.

“I’m excited to see the technology I created continue to evolve into what will hopefully become proven therapies. Clearmind’s first candidate, a treatment for Alcohol Use Disorder, is expected to treat millions of people who have difficulties managing alcohol consumption” Golan commented.

Golan went on, “As the Company embarks on the rigorous regulatory approval process, it’s critical that they have an experienced management team at the helm. I will continue to support Clearmind as Special Advisor for Innovation and New Initiatives. This is a truer representation of my role at the Company and gives me the liberty to more broadly investigate the many indications for psychedelics as medicine.”

Dr. Zuloff-Shani commented on the appointments, “I believe that psychedelic-based medicine has the potential to revolutionize the way we treat mental health issues, and that Clearmind is positioned to become a leader in the field. We have assembled a management team with the expertise and passion necessary to achieve that objective, and we are all eager to get started.”

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic therapeutics to solve widespread and under-served health problems including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods and supplements.

The Company’s intellectual portfolio currently consists of two patent families. “Binge behavior regulators” has been granted in the U.S., Europe, China, and India, with pending divisional applications in Europe and the US. “Alcohol Beverage Substitutes” has been approved for a European patent, with pending applications in the US, China, and India. We will seek additional patents for our compounds whenever warranted and remain opportunistic with regard to the acquisition of additional IP to build our portfolio.

For further information, please contact:

Investor Relations,
Email: [email protected]
Telephone: (778) 400-5347

General Inquiries,
[email protected]
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early stage companies inherently carries a high degree of risk and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to U.S. newswire services or dissemination in the United States.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies https://mjshareholders.com/wake-network-retains-cro-sante-cannabis-to-conduct-clinical-trials-in-psilocybin-therapies/ Wed, 16 Jun 2021 14:57:57 +0000 https://www.cannabisfn.com/?p=2922108

Ryan Allway

June 16th, 2021

Psychedelics


TORONTOJune 16, 2021 /CNW/ – Wake Network Inc. (“Wake” or the Company“), a global leader in psilocybin and medicinal mushroom production and developer of genomics-based integration therapies, is pleased to announce that it has entered into an agreement with Santé Cannabis (“Sante”) for consultation and clinical research services to support Wake clinical trials in Canada. Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin.

This agreement, under which Wake and Santé will collaborate on clinical research initiatives in Canada, is the first of its kind, bringing together an innovative leader in the psychedelic medicine space with a pioneer of medical cannabis research and clinical practice to bring trailblazing discoveries of new and more effective treatment options for patients. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol. With this engagement, Wake finds significant value by capitalizing on Santé’s experience navigating complex regulatory changes and leveraging years of expertise with naturally derived controlled substances.

“Santé is a key partner to for Wake as they are a leading contract research organization (CRO) in Canada with expertise in advancing plant-based pharmaceutical products through various phases of clinical trial development. This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada. Working with such an experienced partner in the field of complementary medicines, we can offer a unique opportunity for physicians to learn about our clinical research program and to broaden their knowledge base on all aspects relating to the benefits of psychedelics,” stated Nick Murray, Chief Executive Officer of Wake.

Under this engagement, in addition to the clinical trials, Santé will also engage with physicians, therapists, and research investigators as partners in psychedelic medicine and research development.

“The opportunity to work with Wake Network, a company committed to the scientific advancement of psychedelic medicines, is one that our team values greatly. Our clinical research and professional training experience has shown us the positive impact of bringing a new clinical tool to physicians. We are excited to explore the potential of emergent psychedelic therapies. Patients deserve more options, and to be assured of the safety and efficacy of their treatments; similarly, physicians deserve answers and are a critical partner in the development of this new therapeutic class,” says Erin Prosk, President of Santé.

Training will be provided within the research program for licensed practitioners to assess the safety of psychedelic medicines and to classify and report positive and adverse events. Wake and Santé will create a portfolio of resources for all licensed practitioners that will include the pillars of safe and effective use including informed consent, harm reduction, patient monitoring and ongoing support.

ABOUT WAKE NETWORK, INC.

Wake Network Inc. is a fungi bioscience company focused on advancing, through research, the field of psychedelic and fungi-based therapeutics. To address the growing need for psychedelic-assisted mental health support in medicine and society at large, Wake has partnered with academics, governments and best-in-class mycologists around the world. Wake is currently developing fungus-derived psilocybin and medicinal mushroom products and is making advancements in the engineering of novel psychedelic biologics, while working on proving out their safety through proprietary genetics-based integration therapies.

ABOUT SANTÉ CANNABIS

Santé Cannabis is a leading medical clinic and research centre dedicated to medical cannabis treatments and complementary medicines. With four clinics in Quebec, Canada, and a network of over 4,000 referring doctors, the multidisciplinary team of physicians and nurses of Santé Cannabis have collected data from, and delivered education to, over 10,000 patients since 2014, through their peer-reviewed world-leading model of care.

Established as Canada’s first independently accredited cannabis Contract Research Organization (CRO) with experience developing and executing cannabis clinical trials, Santé Cannabis is an experienced clinical trial site. They have completed successful healthcare professional training programs in more than five unique countries and are recognized as a university teaching site. Santé Cannabis is at the forefront of safe and supported patient access to complementary medicines.

Caution Regarding Forward-Looking Information

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. 

Forward looking statements are based on certain assumptions regarding the Company, including but not limited to expected growth, results of operations, performance, industry trends and growth opportunities. While the Company considers these assumptions to be reasonable based on currently available information, they may prove to be incorrect. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to: dependence on obtaining and maintaining regulatory approvals, including federal, provincial, municipal, local or other licences, to operate and expand the Company’s facilities;  the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing and the effect of capital market conditions and other factors on the availability of capital; competition, including from more established or better financed competitors; the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers; the Company’s ability to conduct the clinical trials that it intends to;  the ability of the Company to discover new and/or more effective options for patients to treat their conditions; the development and implementation of medical protocols and treatment standard operating procedures for the use of psychedelic therapies; the Company’s ability to successfully withstand the economic impact of COVID-19; the medical benefits, safety, efficacy, dosing and social acceptance of psychedelics; and the cultivation and harvest of psilocybe mushrooms; and any other factors or developments that may hinder the market or the Company’s growth. 

These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

SOURCE Wake Network, Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
BetterLife Pharma Appoints Henri Sant-Cassia of The Conscious Fund to its Board of Directors https://mjshareholders.com/betterlife-pharma-appoints-henri-sant-cassia-of-the-conscious-fund-to-its-board-of-directors/ Wed, 02 Jun 2021 18:18:13 +0000 https://www.cannabisfn.com/?p=2920674

Ryan Allway

June 2nd, 2021

Psychedelics


VANCOUVER, British Columbia, June 02, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce that it has appointed Mr. Henri Sant-Cassia, co-founder of The Conscious Fund, to its Board of Directors.

 

Mr. Sant-Cassia has 10 years of experience working in the plant medicine field and has been a serial entrepreneur since his early twenties. Since 2018, he has been a founding partner at The Conscious Fund, the most active venture fund in the psychedelic medicine space. His expertise includes psychedelic compounds, operating models, venture funding, growth and exit planning, as well as managing media and investor relations campaigns. His work has created over $200 million in company valuations within the psychedelic world, and he previously worked in the manufacturing, retail and research of cannabinoid-based products. He holds a degree in law from University College London. Mr. Sant-Cassia also serves on the boards of Magic Med and Microdose, a media company.

[embedded content]

“I am delighted to be working with Ahmad, who is one of the new breeds of CEOs from the bioscience space, and Patrick, one of the longest serving members of the psychedelic medicine community. We believe that BetterLife has enormous untapped potential, both within second generation psychedelic therapies and in the wider medical field,” commented Mr. Sant-Cassia.

 

“We are extremely pleased to welcome Henri Sant-Cassia to our Board of Directors. He brings a wealth of experience in the psychedelic space, which will be very valuable as we execute our plans to develop non-hallucinogenic compounds to treat depression and other mental health disorders. We look forward to working with The Conscious Fund team and their extensive network within the psychedelic community,” commented Ahmad Doroudian, CEO of BetterLife.

 

BetterLife also announces the resignation of Mr. Sergei Stetsenko from its Board of Directors. The Company thanks Mr. Stetsenko for his contributions to BetterLife.

 

About The Conscious Fund

 

The Conscious Fund is the most active early stage venture fund in the psychedelic medicine space. It invests into drug discovery, clinics, addiction programs, retreats, AI, telemedicine, media and training. Its global, platform-based approach helps to transform outcomes for patients with mental health, addiction and chronic pain issues.

 

The USD$60 million fund has backed 14 of the leading companies in the sector, spanning drug discovery, clinics, addiction, AI, and media, and has incubated 13 projects, including The Psychedelic Medicine Association, the first psychedelic medicine SPAC, and Microdose, a profitable media company.

 

For further information, please visit www.theconscious.fund.

 

About BetterLife Pharma Inc.

 

BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.

 

For further information please visit www.abetterlifepharma.com.

 

Contact Information:

 

Ahmad Doroudian, Chief Executive Officer

 

Email: [email protected]com

 

Phone: 604-221-0595

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Novamind Opens Client Care Center to Support High Demand for Treatments https://mjshareholders.com/novamind-opens-client-care-center-to-support-high-demand-for-treatments/ Tue, 18 May 2021 15:04:18 +0000 https://www.cannabisfn.com/?p=2920469

Ryan Allway

May 18th, 2021

Psychedelics


Invests in care support systems to facilitate rapid expansion

TORONTO, ON / ACCESSWIRE / May 18, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, has opened a new Novamind Client Care Center (“Client Care Center”) to manage the overwhelming demand for its treatments and to support its planned growth to eight clinics by September 2021.

Novamind’s new Client Care Center is located in Murray, Utah, and staffed by highly trained personnel who connect and interact with clients through various communication channels. On an average weekday, Novamind’s Client Care team responds to approximately 700 inbound calls from clients, physicians, and caregivers.

“We are proud of how our clients begin and sustain their therapeutic relationships with our clinics,” said Pierre Bou-Mansour, Chief Operating Officer of Novamind. “As we continue our rapid growth, we remain committed to maintaining a high degree of service while helping new and existing clients access our innovative mental health and psychedelic medicine treatments.”

After completing an intensive 4-8 week training program, Client Care Center specialists provide valuable services including managing client questions, resolving complex issues, and scheduling clients with appropriate providers. Specialists also coordinate physician referral intakes, fulfill prescription medication requests and treatment pre-authorizations, as well as verify and explain insurance benefits to match each client’s unique needs.

The new Client Care Center was opened in response to record demand for treatments. Currently, all clinics have an approximate 2-week wait time to book new appointments. In 2020, Novamind recorded 20,000 client visits, and anticipates 65,000 client visits in 2021, a 225% increase.

“Novamind’s expansion plan is six months ahead of schedule,” reported Yaron Conforti, CEO and Director. “The significant growth in patient visits at our clinics is being supported by strategic investments in care delivery support systems. Our investment in the Client Care Center ensures that Novamind will continue to provide best-in-class mental healthcare as we accelerate our clinic network expansion.”

Clients are welcome to contact Novamind’s Client Care Center at +1 (801) 369-8989.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board https://mjshareholders.com/former-gw-pharmaceuticals-cfo-joins-beckley-psytechs-board/ Tue, 13 Apr 2021 16:14:21 +0000 https://www.cannabisfn.com/?p=2918020

Ryan Allway

April 13th, 2021

Psychedelics


Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed ex-GW Pharmaceuticals CFO Adam George as a director with immediate effect.

Bringing nearly two decades of experience in the pharmaceuticals industry, Adam served as Chief Financial Officer (CFO) for five years at GW Pharmaceuticals, the UK-based drug development company focused on using cannabinoid therapeutics for treating a range of diseases. During this time he oversaw the company’s initial public offering on Nasdaq, and was involved in subsequent fundraisings totalling over $1.4 billion.

Adam went on to serve as UK Managing Director from 2017 until December 2020, where he held joint responsibility for leading GW Pharmaceuticals’ Research and Development programmes. Since 2018, he has also served as Audit Committee Chairman for clinical-stage biopharma NuCana Plc, and has held several senior financial roles across both public and private companies in his 30-year career.

In his role at Beckley Psytech, Adam will be responsible for heading up the company’s Audit Committee and will bring to the Board extensive experience of running major growth businesses in the biopharmaceutical industry.

Adam joins the company at an exciting time following a highly successful USD $18m funding round in December 2020, and UK regulatory approval to begin a ground-breaking clinical trial exploring the effects of low-dose psilocybin for treating a rare and debilitating headache condition known as short-lasting unilateral neuralgiform headache attacks (SUNHA).

Cosmo Feilding Mellen, CEO at Beckley Psytech, says: “Adam brings a wealth of senior-level experience in scaling promising life sciences companies, including leading the highly successful Nasdaq IPO for GW Pharmaceuticals during his time as CFO. His knowledge and experience of developing controlled drugs into FDA-approved pharmaceutical medicines for patients in need is particularly relevant for us, and I’ve no doubt Adam’s stewardship on the board will be invaluable to Beckley Psytech as we continue on our own rapid growth journey.”

Adam George, Independent Director at Beckley Psytech, says: “I am delighted to be joining the Beckley Psytech team at this exciting time. I see so many parallels between GW’s cannabis pharmaceutical development story and Beckley Psytech’s mission to develop a pipeline of pharmaceutical medicines from psychedelic molecules for the benefit of patients, and hope that I can apply my GW experience to help the company continue on its ambitious trajectory.”

 

-Ends-

For more information, please contact:

Four Communications

Anthony Cornwell / Max Gibson / Julia Niedoborek

+44 20 3697 4200

[email protected]

Notes to editors

You can download an image of Adam here.

Beckley Psytech

Founded in 2019, Beckley Psytech is a private company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into approved pharmaceutical treatments. Our vision, supplemented by our partnership with the Beckley Foundation, is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients in need around the world suffering with these profoundly debilitating conditions.

www.beckleypsytech.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>